Streetbeat News

Stock Prices

AMGN

Financial analysis reveals a bearish trend in Amgen's (NASDAQ:AMGN) options trading, with 53% of traders showing bearish tendencies. Significant trades indicate a targeted price range of $290.0 to $305.0. Amgen, a biotech leader, has a diverse portfolio including drugs for cancer, inflammatory diseases, and rare diseases. The stock is currently down -0.38% at $290.01, with analysts giving mixed ratings but an average target price of $338.6. Options trading suggests cautious investor sentiment despite Amgen's strong market standing and analyst support.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

LRCX

Lam Research (LRCX) is analyzed against competitors in the Semiconductors & Semiconductor Equipment industry, highlighting its market position, financial metrics, and growth prospects. LRCX shows potential for growth with a lower PE ratio than the industry average but appears overvalued based on its PB and PS ratios. Despite strong profitability indicators like high ROE, EBITDA, and gross profit, LRCX's revenue growth significantly lags behind the industry average.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

RNLX

Trading of Renalytix (RNLX) shares has resumed, indicating a return to normal trading activities for the company.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 4:00 pm

KKR

KKR & Co (NYSE:KKR) is analyzed against its Capital Markets industry peers, showing strong financial performance with a lower PE ratio, higher ROE, EBITDA, gross profit, and remarkable revenue growth. The company's asset management and insurance segments contribute to its $518.5 billion in AUM. Despite a high PS ratio suggesting overvaluation based on sales, KKR's overall metrics indicate potential for growth and undervaluation in other areas.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

IIIV

In the last three months, 6 analysts have rated i3 Verticals (NASDAQ:IIIV) with a mix of indifferent and somewhat bullish perspectives. The average 12-month price target for IIIV has been adjusted to $25.83, down from $26.50, indicating a slight decrease in analyst expectations. The company's financial performance shows a revenue decline of -4.58% over the past 3 months, a net margin of 1.19%, and an ROE of 0.46%, suggesting efficient cost management but challenges in revenue growth and high debt levels with a debt-to-equity ratio of 1.62.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

DTE

Recent analyst ratings for DTE Energy (NYSE:DTE) show a mix of perspectives, with 2 somewhat bullish and 3 indifferent ratings in the last three months. The average 12-month price target is $113.2, indicating a 4.33% increase from the previous target of $108.50. Analysts from BMO Capital, Guggenheim, Keybanc, and Evercore ISI Group have adjusted their ratings and price targets, reflecting their views on DTE Energy's market position. Despite a negative revenue trend of -24.17% over 3 months, DTE Energy exhibits strong financial health with a net margin of 12.32%, an ROE of 3.82%, and an ROA of 0.94%.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

EWBC

East West Bancorp (NASDAQ:EWBC) has delivered an average annual return of 16.12% over the past 15 years, outperforming the market by 3.03% annually. A $100 investment in EWBC 15 years ago would now be worth $941.34. The company currently has a market capitalization of $9.72 billion.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

FCFS

Over the past 20 years, FirstCash Hldgs (NASDAQ:FCFS) has delivered an average annual return of 12.65%, outperforming the market by 5.02% on an annualized basis. With a current market capitalization of $5.34 billion, an initial investment of $100 in FCFS 20 years ago would now be worth $1,074.07. This showcases the significant impact of compounded returns on cash growth over time.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

ABT

EW

FDA advisors will discuss Abbott Laboratories' TriClip G4 System for severe tricuspid regurgitation (TR) on February 13, 2024. Despite the TRILUMINATE trial meeting its primary endpoint, FDA reviewers raised concerns about the trial's unblinded design and the potential placebo effect on patient-reported outcomes. Earlier, Edwards Lifesciences received FDA approval for its Evoque tricuspid valve replacement system without an advisory committee, based on positive TRISCEND II study results. ABT shares fell 0.38% to $111.38.

Portfolio Pulse from Vandana Singh

February 12, 2024 | 4:00 pm

ASML

INTC

SSNLF

TSM

ASML Holding NV showcased its advanced €350 million chipmaking machine, ordered by Intel Corp for its Oregon factory, aiming for production by late 2025. This machine, critical for AI advancements, etches semiconductor lines as thin as 8 nanometers. ASML's technology has seen record orders, including from Samsung Electronics and Taiwan Semiconductor Manufacturing Co, reflecting strong industry optimism. ASML reported a 12.5% year-on-year increase in Q4 2023 net sales, with China being its largest market.

Portfolio Pulse from Anusuya Lahiri

February 12, 2024 | 3:58 pm